Multi-Color Fluorescence Microscopy Application using Novel Brilliant Violet™ and Alexa Fluor® 594 Conjugated Monoclonal Antibodies
Poster May 12, 2014
Hong Zhang, Kelly Lundsten, Kevin Williams, Beibei Ding, Xiao Lin, Xifeng Wang, Jie Zhou, Dzung Nguyen, and John Ransom
BioLegend has generated a large library of high affinity antibody clones against different mouse and human antigens that are validated in flow cytometry applications. They are offered as conjugates with the violet-excited Brilliant Violet™ (BV™) fluorophores. Use of the BV™ fluorophores has greatly increased phenotypic multiplexing capabilities in flow cytometry by increasing the utility of the violet laser. Violet-excited BV421™ antibody conjugates are at least as bright as yellow/green-excited phycoerythrin (PE) and red-excited Alexa Fluor® 647 conjugates. The brightness of violet-excited BV510™ is more on par with the green-excited Alexa Fluor® 488. BV421™ and BV510™ are far brighter and more photostable than the violet-excited Alexa Fluor® 405 and Pacific Blue™. Here, using a variety of discrete immunologic cell populations bearing different antigens, BV421™, BV510™, Alexa Fluor® 488, Alexa Fluor® 594 and Alexa Fluor® 647 are shown to also increase multiplexing capabilities and increase resolution in fluorescence microscopy applications. The results show that BV421™, Alexa Fluor® 488, Alexa Fluor® 594 and Alexa Fluor® 647 conjugated monoclonal antibodies are valuable new tools for the immunologist wanting to resolve multiple antigens simultaneously with fluorescence microscopy
Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy TargetsPoster
The human immune system is comprised of a complex network of immune checkpoint receptors that are promising new immunotherapy targets for the treatment of a variety of diseases including cancer and autoimmune-mediated disorders.READ MORE
Reporter Bioassays to Assess Therapeutic Antibodies for Immunotherapy ProgramsPoster
Immunotherapy, also called biologic therapy or biotherapy, stimulates certain parts of the immune system to fight diseases such as cancer. Important drug targets in immunotherapy include: Co-inhibitory receptors, such as PD-1/PD-L1, CTLA-4, LAG3, Tim3; and co-stimulatory receptors, such as GITR, CD40, OX40, 4-1BB.
Current approaches to assaying these targets are cumbersome and variable. Here we offer an improved in vitro bioassay approach.
Modelling CLL cell and T-cell Migration in a Dynamic Circulating Model of CLLPoster
We have recently developed a novel circulating model of chronic lymphocytic leukaemia (CLL) that mimics the transient interactions that take place between circulating lymphocytes and vascular endothelium. Here we show that both normal and malignant lymphocytes actively underwent transendothelial migration.READ MORE
Comments | 0 ADD COMMENT
U.S. FDA Accepts Licence For Biosimilar Trastuzumab
News Jan 12, 2017